Pharmareview Corporation

Biotech

Recombinant human lactoferrin (rhLF) protein therapeutic for immune modulation in tuberculosis

Grants
$5.3M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Lactoferrin Modulation of Granuloma Pathology$224,725
Federal grantDepartment of Health and Human Services · Phase I · Optimized lactoferrin for treatment of intracerebral hemorrhage$47,600
Federal grantDepartment of Health and Human Services · Phase II · Optimized lactoferrin for treatment of intracerebral hemorrhage$1,604,091
Federal grantDepartment of Health and Human Services · Phase II · Optimized lactoferrin for treatment of intracerebral hemorrhage$827,468
Federal grantDepartment of Health and Human Services · Phase II · Lactoferrin Modulation of Granuloma Pathology$1,696,381
Federal grantDepartment of Health and Human Services · Phase II · Lactoferrin Modulation of Granuloma Pathology$881,060
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3050PROTEIN POTENTIAL LLC——
3051Alentis Therapeutics——
3052OLFA THERA, INC.——
3053Pharmareview Corporation——
3054BIOSETTIA, INC.——
3055VEANA THERAPEUTICS LLC——
3056NANONEWRON LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.